• Iovance Biotherapeutics Says Cervical Cancer Drug Has 11% Response Rate in Study

    Iovance Biotherapeutics (IOVA) said Friday its drug LN-145 achieved an 11% complete response rate in a follow-up study of patients with advanced cervical cancer. The company noted that the median duration of response (DOR) had yet to be reached in the trial. “The duration of response of current second line treatments for advanced cervical cancer are in the range of […]

  • Balfour Beatty – Fluor JV Conditionally Bags $1.7 Billion Texas Highway Contract

    Balfour Beatty (BBY.L), a British infrastructure group, said early Friday that it has been conditionally awarded a $1.7 billion interstate highway contract from the Department of Transportation in Texas as part of a joint venture with Fluor (FLR). The company said in a statement that it has a 45% share in the joint venture, while Fluor, an engineering and construction […]